Komori
JCR Pharmaceuticals (4552) · PolicyUpdate to compliance operating metrics

Strengthening Compliance, Transparency and Internal Controls

First written in FY2016. 4 of 10 entries say "Advanced", first in FY2021. Latest entry: FY2026.

10entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019AdvancedFY2021 – FY20242016: 120162017: 120172018: 120182019: 120192020: 020202021: 120212022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Integrated Strengthening of Internal Controls, Corporate Governance and ComplianceA theme 354 companies write about · 2 as a headwind · 353 as a tailwind

8 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 355 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Update to compliance operating metricsAnnual report

    「① Number of communication activities between officers and employees: 13 ② Rate of response to recommendations for improvement from ongoing evaluations of Board effectiveness (target: 100%): 100% ④ Number of whistleblowing cases handled: 17」

    The company disclosed 13 communication activities between officers and employees, a 100% response rate to recommendations for improving Board effectiveness, and 17 whistleblowing cases handled.
  2. FY2025Update to whistleblowing response resultsAnnual report

    「④ Number of whistleblowing cases handled: 11」

    The company disclosed 11 whistleblowing cases handled during the period as a compliance and internal control operating metric. The figure was updated from the 16 cases disclosed for the previous period.
  3. FY2024AdvancedAnnual report

    「To promote compliance, we hold regular meetings, approve compliance action plans and policies, provide employee training and education in accordance with the compliance code of conduct and compliance handbook, and disseminate and promote awareness through compliance communications.」

    The company continued its operating framework covering approval of compliance action plans and policies, handbook-based training, regular communications and whistleblowing response, and disclosed performance metrics including 16 whistleblowing cases handled.
  4. FY2023AdvancedAnnual report

    「To promote compliance, we hold regular meetings, approve compliance action plans and policies, provide employee training and education in accordance with the compliance code of conduct and compliance handbook, and disseminate and promote awareness through compliance communications.」

    The company disclosed in detail its operating framework, including approval of compliance action plans and policies, handbook-based training, whistleblowing and coordination with the Internal Control Committee, in addition to the existing training and communications.
  5. FY2022AdvancedAnnual report

    「In response to a series of scandals in the industry, we launched a new training program to prevent misconduct within the company and are strengthening compliance education for all employees beyond previous levels.」

    In addition to the existing compliance training and communications, the company launched a new training program to prevent misconduct. It also described company-wide risk prevention by the Risk Management Promotion Council and the formulation of a BCP.
  6. FY2021AdvancedAnnual report

    「We have identified and listed the key risks that the company should recognize, selected and formulated the following 3 items as business continuity plan (BCP) measures, and will review the BCP each fiscal year and revise it as necessary.」

    The internal control and compliance framework incorporates a list of key risks and a BCP covering disruptions to the supply of Growject®, large-scale disasters and serious compliance violations.
  7. FY2019RestatedAnnual report

    「To remain a company loved and trusted by all stakeholders, we will continue to proactively strengthen our management foundation, including by ensuring thorough compliance based on the high ethical and moral standards expected of a pharmaceutical company, further strengthening corporate governance and increasing transparency in our corporate activities, with the aim of achieving sustainable growth.」

    The company reaffirmed its policy of maintaining compliance, strengthening governance and increasing transparency in its corporate activities.
  8. FY2018RestatedAnnual report

    「To remain a company loved and trusted by all stakeholders, we will continue to proactively strengthen our management foundation, including by ensuring thorough compliance based on the high ethical and moral standards expected of a pharmaceutical company, further strengthening corporate governance and increasing transparency in our corporate activities, with the aim of achieving sustainable growth.」

    The company reaffirmed its policy of maintaining compliance based on high ethical standards, strengthening governance and increasing transparency in its corporate activities.
  9. FY2017RestatedAnnual report

    「We will enhance initiatives such as internal training conducted by the Compliance Committee and awareness-raising activities through the regular publication of compliance communications, establish a structure that enables directors and employees to maintain a high level of awareness of compliance at all times, and work to prevent violations of laws and regulations.」

    The company described in detail its ongoing framework for compliance with laws and regulations, transparency and internal controls through compliance training, regular communications and internal audits.
  10. FY2016First statedAnnual report

    「To remain a company loved and trusted by all stakeholders, including our customers and employees, we will continue to value the free-spirited corporate culture established at our founding and proactively pursue further strengthening of compliance and corporate governance, greater transparency in our corporate activities and the realization of diversity, with the aim of achieving sustainable growth.」

    The company identifies compliance, corporate governance, transparency in corporate activities and diversity as issues to be addressed for sustainable growth.
Moved together

"Commercialization, Joint Research and Licensing of J-Brain Cargo®" moved the same way as this thread, in the same document, in 4 of its 10 moves.

444444★123456
  1. ★This thread
  2. 1Commercialization, Joint Research and Licensing of J-Brain Cargo®4×
  3. 2Expanding revenue from core products and strengthening the product portfolio4×
  4. 3Expansion of Proprietary Biopharmaceutical Platform Technology4×
  5. 4Development of a Manufacturing and Cell Processing Center for Investigational Drugs4×
  6. 5Developing Talent with a Spirit of Challenge and Advancing Diversity4×
  7. 6Creation of Innovative Pharmaceuticals for Intractable and Rare Diseases4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Compliance, Transparency and Internal Controls | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori